Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development

Abstract

Our results support the notion that increasing the number of circulating endothelial progenitor cells by different ways could be a promising therapeutic tool for atherosclerosis.

Microparticles of healthy origins improve endothelial progenitor cell dysfunction via microRNA transfer in an atherosclerotic hamster model

“…The generation of experimental diet model of atherosclerosis, the source for late EPC culture For this study, 60 male Golden Syrian hamsters aged 3 months were split into: (i) hypertensive-hyperlipidaemic hamsters (HH group)obtained by administering an ordinary feed enriched in 3% cholesterol, 15% butter and 8% NaCl, for 4 months; and (ii) control hamsters (C group)healthy animals who received classical food containing 1% NaCl. [29][30][31][32][33]70,71 Both groups of animals were kept under the same housing conditions that respect their needs.…”

Ligustrazine inhibits platelet activation via suppression of the Akt pathway

“…Platelet activation is an essential process to repair injured blood vessels, restoring blood vascular integrity, which is fundamental for the maintenance of vascular function. However, aberrant platelet activation or hyperactivation of platelets may give rise to thrombosis and result in thrombotic vascular events, including atherosclerosis, arterial thrombosis and myocardial infarction (1)(2)(3)(4)(5). Under physiological conditions, platelets circulate through vessels with an intact and healthy endothelium, remaining in an inactivated state.…”

Effects of endothelial progenitor cells transplantation on hyperlipidemia associated kidney damage in ApoE knockout mouse model

“…Therefore, despite the relative paucity of data on the therapeutic effects of EPCs on hyperlipidaemia-associated kidney damage, prior atherosclerosis studies provide ample support for the use of EPCs in animal models of hyperlipidaemia. In a mouse model of hypertension-hypercholesterolemia, the administration of EPCs reduced hepatic lipid accumulation and consequently alleviated hypertension and dyslipidaemia [26]. In contrast, Silvestre et al found that EPC treatment aggravated the atherosclerosis burden when EPCs were transferred from young to old ApoE −/− mice [7].…”